This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Mar;8(3):221-2.

doi: 10.1016/S1474-4422(09)70022-5. Epub 2009 Feb 7.

Getting the measure of multiple sclerosis

PMID: 19201655
DOI: 10.1016/S1474-4422(09)70022-5

Comment

Getting the measure of multiple sclerosis

Lael A Stone. Lancet Neurol. 2009 Mar.

. 2009 Mar;8(3):221-2.

doi: 10.1016/S1474-4422(09)70022-5. Epub 2009 Feb 7.

Author

PMID: 19201655
DOI: 10.1016/S1474-4422(09)70022-5

No abstract available

PubMed Disclaimer

Comment on

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Havrdova E, et al. Lancet Neurol. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7. Lancet Neurol. 2009. PMID: 19201654 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information